Full Breakdown
Daraxonrasib Shows Near-Doubling of Survival in Pancreatic Cancer at ASCO 2026
6/3/2026, 10:05:51 PM
Core Trial Findings
The experimental oral agent daraxonrasib, a targeted therapy, was evaluated in a trial by Revolution Medicines. Patients receiving daraxonrasib lived nearly twice as long as those given standard chemotherapy, an outcome not previously seen in pancreatic cancer. Results were presented at the ASCO plenary session and published in the New England Journal of Medicine.
Background
Pancreatic cancer has limited systemic treatment options, with standard chemotherapy as the primary approach. Advances have yielded modest survival gains and the disease carries poor prognosis. A targeted oral agent achieving a near-doubling of overall survival therefore departs from typical incremental improvements.
Key Contributors and Institutions
Key contributors include Dr. Rachna Shroff, a pancreatic cancer specialist at the University of Arizona Cancer Center; Revolution Medicines, the developer of daraxonrasib; the American Society of Clinical Oncology (ASCO), which hosted the plenary session; the New England Journal of Medicine (NEJM), which published the findings; and Adam Feuerstein, senior writer for STAT who reported the study.
Data Overview
The primary endpoint was overall survival. Patients on daraxonrasib had overall survival “nearly twice” that of those on standard chemotherapy. No further numeric details are provided.
Official Summaries and Responses
Revolution Medicines reported a statistically significant survival advantage for daraxonrasib over chemotherapy. Dr. Shroff, with 16 years treating pancreatic cancer, called the findings “incredibly impactful” for patients. The ASCO plenary and NEJM publication disseminate the data to the oncology community.
Verbatim Quote
“Having treated pancreatic cancer for 16 years, I actually started crying in the clinic,” Shroff said at a media briefing. “This is such an incredibly impactful study for our patients.” — Dr. Rachna Shroff, University of Arizona Cancer Center
Implications
The observed survival benefit may have significant implications for patients and could influence future therapeutic strategies in pancreatic cancer. If the magnitude of the benefit is confirmed, clinicians may consider daraxonrasib as a treatment option, and research may increasingly focus on targeted approaches.
Conflicting Reports & Gaps
The source provides only overall survival data, lacking safety, adverse-event, and long-term outcome details.
Timeline of Key Events
- April 2026: Dr. Rachna Shroff learns of striking clinical results for daraxonrasib while seeing patients at the University of Arizona Cancer Center.
- May 31 2026: STAT publishes a report on the trial, authored by Adam Feuerstein.
- Sunday (ASCO meeting): Detailed results presented at the plenary session of the American Society of Clinical Oncology.
- Simultaneously: Findings published in the New England Journal of Medicine.
